Octreotide
| Evidence Level: L5 | Predicted Indications: 2 |
Table of Contents
Octreotide: From Acromegaly to Vulvar Inverted Follicular Keratosis
One-Sentence Summary
Octreotide is a somatostatin analogue originally used to treat acromegaly, hyperpituitarism, and carcinoid syndrome. The TxGNN model predicts it may be effective for Vulvar Inverted Follicular Keratosis, but there are currently 0 clinical trials and 0 publications supporting this direction. The prediction rests on the model alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Acromegaly (also hyperpituitarism and carcinoid syndrome) |
| Predicted New Indication | Vulvar inverted follicular keratosis (a second prediction, seborrheic keratosis, scored 99.55%) |
| TxGNN Prediction Score | 99.58% |
| Evidence Level | L5 |
| US Market Status | Cancelled only |
| Number of NDAs | 14 (all cancelled) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the data compiled for this report. Based on known pharmacology, octreotide is a somatostatin analogue that acts on somatostatin receptors (mainly SSTR2 and SSTR5). Its efficacy in acromegaly and carcinoid syndrome is established, and it works by suppressing hormone secretion, including growth hormone and, through it, IGF-1.
A possible link to the predicted indication is that somatostatin receptors may be present in epidermal or follicular keratinocytes, and receptor agonism could slow keratinocyte proliferation or growth-factor signaling. This is speculation with no supporting data.
The second predicted indication, seborrheic keratosis, is a closely related benign keratinocytic lesion. The two high scores may reflect shared neighbors in the knowledge graph rather than a true pharmacological link. These lesions are usually managed with local procedures such as cryotherapy or curettage, so a systemic injectable peptide would have an unfavorable risk-benefit profile without strong supporting evidence.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
US Market Information
All 14 US authorizations are listed as cancelled. The main ones are below; approved indication text was not available for them.
| Authorization Number | Product Name | Dosage Form | Manufacturer |
|---|---|---|---|
| NDA019667 | Sandostatin | Injection, solution | Novartis Pharmaceuticals Corporation |
| NDA208232 | Mycapssa | Capsule, delayed release | Chiesi USA, Inc. |
| NDA213224 | BYNFEZIA Pen | Injection | Sun Pharmaceutical Industries, Inc. |
| ANDA076330 | Octreotide Acetate | Injection, solution | Hikma Pharmaceuticals USA Inc. |
| ANDA077450 | Octreotide | Injection, solution | Fresenius Kabi USA, LLC |
Safety Considerations
Contraindication-related conditions (from the drug-disease knowledge graph, not label text): hyperglycemia, hypoglycemia, diabetes mellitus, diabetic ketoacidosis, hypothyroidism (including myxedema and congenital hypothyroidism), gallbladder disease and gallstones (cholelithiasis, cholecystolithiasis, choledocholithiasis), liver disease and cirrhosis, kidney failure and uremia, ileus and intestinal obstruction, sudden cardiac arrest, heart conduction disease, and vitamin B12 deficiency.
Drug Interactions: 100 interactions were found in total, and all 20 shown in the data are rated Moderate. They are mainly glucose-lowering drugs, so blood glucose should be monitored when octreotide is combined with them. Examples include:
- Insulins (aspart, degludec, detemir, glargine, glulisine, human insulins)
- Metformin, acarbose, chlorpropamide, glimepiride
- GLP-1 agonists (albiglutide, dulaglutide, semaglutide)
- DPP-4 inhibitors (alogliptin, linagliptin)
- SGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflozin)
Please refer to the package insert for label warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has no clinical or literature support (evidence level L5) and only a speculative mechanistic link. The drug has no currently valid US authorization, and the indication is a benign skin lesion for which effective local treatments already exist.
To proceed, the following is needed:
- Mechanism of action data, including evidence of somatostatin receptor expression in keratinocytic lesions
- Preclinical or early clinical evidence in vulvar inverted follicular keratosis or seborrheic keratosis
- Official package insert warnings and contraindications for safety screening
- Assessment of route compatibility (systemic injection versus topical or local treatment) and of regulatory status, since all US authorizations are cancelled
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.